We provide you with 20 years of free, institutional-grade data for ACIU stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ACIU. Explore the full financial landscape of ACIU stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Zuegel Martin | Initial | 2026-04-01 | |||
| Donati Piergiorgio | Initial | 2026-03-20 | |||
| Roberts Christopher James | Initial | 2026-03-18 | |||
| Buetler Monika | Initial | 2026-03-18 | |||
| Twyman Roy Ervin | Initial | 2026-03-18 | |||
| AGUIAR-LUCANDER RENEE | Initial | 2026-03-18 | |||
| Pfeifer Andrea | Initial | 2026-03-18 | |||
| June Carl Howard | Initial | 2026-03-18 |
The information provided in this report about ACIU stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
AC Immune SA(NASDAQ:ACIU) 
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, ...
Website: http://www.acimmune.com
Founded: 2003
Full Time Employees: 115
CEO / Founder: Andrea Pfeifer
Sector: Healthcare
Industry: Biotechnology